Potential for the Use of Probiotics in Clinical Medicine | CMAC

Potential for the Use of Probiotics in Clinical Medicine

Clinical Microbiology and Antimicrobial Chemotherapy. 2006; 8(2):151-172

​ Andreeva I.V.
probiotics prebiotics antibiotic-associated diarrhea GI infections inflammatory bowel diseases prophylactic use safety
Section
Antimicrobials
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2006; 8(2):151-172

Abstract

Currently, prophylactic and therapeutic use of probiotics is a common practice worldwide, although their effectiveness remains controversial. This review presents data on main probiotic microorganisms. This paper summarizes available evidence-based data on the rationale for the prophylactic and therapeutic use of probiotics as well as current approaches to their use for treatment and prevention both infectious and non-infectious GI tract conditions/diseases, primarily antibiotic-associated diarrhea, GI infections, inflammatory bowel diseases, H. pylori eradication therapy. The magnitude of probiotics in the prevention of infections (especially, respiratory tract infections) in adults and children, and the potential for the use of this drug class in the treatment of allergy, female genitourinary tract infections, surgical diseases, and their promising use in the other fields of clinical medicine are also considered. A focus on safety issues concerning the use of probiotics is made.

  • 1. Metchnikoff E. Lactic acid as inhibiting intestinal putrefaction. In: Chalmers Mitchell P, ed. The prolongation of life: optimistic studies. London: Heinemann, 1907; 161-83.
  • 2. Lilly D. M., Stilwell R. H. Probiotics: growth promoting factors produced by microorganisms. Science 1965; 147:747-8.
  • 3. Fuller R. Probiotics in man and animals. J Appl Bacteriol 1989; 66:365-78.
  • 4. Reid G. Regulatory and clinical aspects of dairy probiotics. FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Powder Milk with Live Lactic Acid Bacteria. Cordoba, Argentina, 2001, 1-34. Available from: http://www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf
  • 5. Hoesl C.E., Altwein J.E. The probiotic approach: an alternative treatment option in urology. Eur Urol 2005; 47:288-96.
  • 6. Gibson G.R., Roberfroid M.B. Dietary modulation of the human colonic micro-biota: introducing the concept of prebiotics. J Nutr 1995; 125:1401-12.
  • 7. Tanaka R., Takayama H., Morotomi М., et al. Effect of administration TOS and Bifidobacterium breve 4006 on the human fecal flora. Bifidobacteria microflora 1983; 2:17-24.
  • 8. Roberfroid M.B. Prebiotics and probiotics: are they functional foods? Am J Clin Nutr 2000; 71(Suppl 6):1682S-87S.
  • 9. Van Loo J., Cummings J., Delzenne N., et al. Functional food properties of non-digestible oligosaccharides: a consensus report from the HVDO project (DGXII AIRII-CT94-1095). Br J Nutr 1999; 81:121-32.
  • 10. Rowland I.R., Tanaka R. The effects of transgalactosylated oligosaccharides on gut flora metabolism in rats associated with a human faecal microflora. J AppI Bacteriol 1993; 74:667-74.
  • 11. Eaton T.J., Gasson M.J. Molecular screening of Enterococcus virulence determinants and potential for genetic exchange between food and medical isolates. Appl Environ Microbiol 2001; 67:1628-35.
  • 12. Holzapfel W.H., Haberer P., Geisen R., et al. Taxonomy and important features of probiotic microorganisms in food and nutrition. Am J Clin Nutr 2001; 73(2 Suppl):365S-73S.
  • 13. Guidelines for the Evaluation of Probiotics in Food. Joint FAO/WHO (Food and Agriculture Organization/World Health Organisation) Working Group. London, Ontario, Canada: 2002.
  • 14. Adams M.R., Marteau P. On the safety of lactic acid bacteria from food. Int J Food Microbiol 1995; 27:263-4.
  • 15. Naidu A.S., Bidlack W.R., Clemens R.A. Probiotic spectra of lactic acid bacteria (LAB). Crit Rev Food Sci Nutr 1999; 39:113-126.
  • 16. Reid G. Safety of Lactobacillus strains as probiotic agents. Clin Infect Dis 2002; 35:349-50.
  • 17. Salminen S., von Wright A., Morelli L., et al. Demonstration of safety of probiotics – a review. Int J Food Microbiol 1998; 44:93-106.
  • 18. Borriello S.P., Hammes W.P., Holzapfel W., et al. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis 2003; 36:775-80.
  • 19. Marteau P., Seksik P., Jian R. Probiotics and health: new facts and ideas. Curr Opin Biotechnol 2002; 13:486-9.
  • 20. Mackay A.D., Taylor M.B., Kibbler C.C., Hamilton-Miller J.M.T. Lactobacillus endocarditis caused by a probiotic organism. Clin Microbiol Infect 1999; 5:290-2.
  • 21. Rautio M., Jousimies-Somer H., Kauma H., et al. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 1999; 28:1159-60.
  • 22. Salminen M.K., Rautelin H., Tynkkynen S., et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis 2004; 38:62-9.
  • 23. Land M.H., Rouster-Stevens K., Woods C.R., et al. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005; 115:178-81.
  • 24. De Groote M.A., Frank D.N., Dowell E., et al. Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome. Pediatr Infect Dis J 2005; 24:278-80.
  • 25. Hennequin C., Kauffmann-Lacroix C., Jobert A., et al. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis 2000; 19:16-20.
  • 26. Cherifi S., Cherifi S., Robberecht J., Miendje Y. Saccharomyces cerevisiae fungemia in an elderly patient with Clostridium difficile colitis. Acta Clin Belg 2004; 59:223-4.
  • 27. Riquelme A.J., Calvo M.A., Guzman A.M., et al. Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients. J Clin Gastroenterol 2003; 36:41-3.
  • 28. Lestin F., Pertschy A., Rimek D. Fungemia after oral treatment with Saccharomyces boulardii in a patient with multiple comorbidities. Dtsch Med Wochenschr 2003; 128:2531-3.
  • 29. Munoz Р., Bouza E., Cuenca-Estrella M., et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005; 40:1625-34.
  • 30. Oggioni M.R., Pozzi G., Balensin P.E., et al. Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis. J Clin Microbiol 1998; 36:325–6.
  • 31. Richard V., Auwera P., Snoeck R., et al. Nosocomial bacteremia caused by Bacillus species. Eur J Clin Microbiol Infect Dis 1988; 7:783-5.
  • 32. Gardiner D., Murphey S., Ossman E., Jungkind D. Prevalence and acquisition of vancomycin-resistant enterococci in a medical intensive care unit. Infect Control Hosp Epidemiol 2002; 23:466-8.
  • 33. Salminen M.K., Tynkkynen S., Rautelin H., et al. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis 2002; 35:1155-60.
  • 34. Tannock G.W., Tilsala-Timisjarvi A., Rodtong S., еt аl. Identification of Lactobacillus isolates from the gastrointestinal tract, silage, and yoghurt by 16S-23S rRNA gene intergenic spacer region sequence comparisons. Appl Environ Microbiol 1999; 65:4264-7.
  • 35. Reid G., Jass J., Sebulski M.T., McCormick J.K. Potential uses of probiotics in clinical practice. Clin Microbiol Rev 2003; 16:658-72.
  • 36. Huang J., Bousvaros A., Lee J., et al. Efficacy of probiotic use in acute diarrhea in children, a meta-analysis. Dig Dis Sci 2002; 47:2625-34.
  • 37. Allen S.J., Okoko B., Martinez E., et al. Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev 2004; (2):CD003048.
  • 38. Van Niel C.W., Feudtner C., Garrison M.M., et al. Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. Pediatrics 2002; 109:678-84.
  • 39. McFarland L.V. Diarrhea acquired in the hospital. Gastroenterol Clin North Am 1993; 22:563-77.
  • 40. Castagliuolo I., Riegler M.F., Valenick L., et аl. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 1999; 67:302-7.
  • 41. Plummer S., Weawer M., Dee P., Hunter J. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C.difficile diarrhea. Int Мicrobiоl 2004; 7:59-62.
  • 42. Cremonini F., Di Caro S., Nista E.C., et al. Metaanalysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2002; 16:1461-7.
  • 43. D’Souza A.L., Rajkumar C., Cooke J., Bulpitt C.J. Probiotics in prevention of antibiotic associated diarrhea: meta-analysis. BMJ 2002; 324:1361.
  • 44. Szajewska H., Mrukowicz J. Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2005; 22:365-72.
  • 45. Schultz M., Timmer A., Herfarth H.H., et al. Lactobacillus GG in inducing and maintaining remission of Crohn’s disease. BMC Gastroenterol 2004; 4:5.
  • 46. Malchow H.A. Crohn’s disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn’s disease? J Clin Gastroenterol 1997; 25:653-8.
  • 47. Guslandi M., Mezzi G., Sorghi M. Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Dig Dis Sci 2000; 45:1462-4.
  • 48. Gionchetti P., Rizzello F., Venturi A., et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119:305-9.
  • 49. Mimura T., Rizzello F., Helwig U., et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53:108-14.
  • 50. Kuisma J., Mentula S., Jarvinen H., et al. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 2003; 17:509-15.
  • 51. Gionchetti P., Rizzello F., Helwig U., et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003; 124:1202-9.
  • 52. Gosselink M.P., Schouten W.R., van Lieshout L.M., et al. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum 2004; 47:876-84.
  • 53. Boyanova L., Mentis A., Gubina M., et al. The status of antimicrobial resistance of Helicobacter pylori in Еastern Europe. Clin Microbiol Infect 2002; 8:388-96.
  • 54. Armuzzi A., Cremonini F. Bartolozzi F., et al. The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2001; 15:163-9.
  • 55. Canducci F., Armuzzi A., Cremonini F., et al. A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment Pharmacol Ther 2000; 14:1625-9.
  • 56. Cats A., Kuipers E.J., Bosschaert M.A., et al. Effect of frequent consumption of a Lactobacillus casei-containing milk drink in Helicobacter pylori-colonized subjects. Aliment Pharmacol Ther 2003; 17:429-35.
  • 57. Cremonini F., Di Caro S., Covino M., et al. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002; 97:2744-9.
  • 58. Felley C.P., Corthesy-Theulaz I., Rivero J.L., et al. Favourable effect of an acidified milk (LC-1) on Helicobacter pylori gastritis in man. Eur J Gastroenterol Hepatol 2001; 13:25-9.
  • 59. Michetti P., Dorta G., Wiesel P.H., et al. Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Digestion 1999; 60:203-9.
  • 60. Mrda Z., Zivanovic M., Rasic J., et al. Therapy of Helicobacter pylori infection using Lactobacillus acidophilus. Med Pregl 1998; 51:343-5.
  • 61. Pantoflickova D., Corthesy-Theulaz I., Dorta G., et al. Favourable effect of regular intake of fermented milk containing Lactobacillus johnsonii on Helicobacter pylori associated gastritis. Aliment Pharmacol Ther 2003; 18:805-13.
  • 62. Sakamoto I., Igarashi M., Kimura K., et al. Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans. J Antimicrob Chemother 2001; 47:709-10.
  • 63. Sheu B.S., Wu J.J., Lo C.Y., et al. Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002; 16:1669-75.
  • 64. Wendakoon C.N., Thomson A.B., Ozimek L. Lack of therapeutic effect of a specially designed yogurt for the eradication of Helicobacter pylori infection. Digestion 2002; 65:16-20.
  • 65. Wang K.-Y., Li S.-N., Liu C.-S., et al. Effects of ingesting Lactobacillus- and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori. Am J Clin Nut 2004; 80:737-41.
  • 66. Sykora J., Valeckova K., Amlerova J., et al. Effects of a specially designed fermented milk product containing probiotic Lactobacillus casei DN-114 001 and the eradication of H. pylori in children: a prospective randomized double-blind study. J Clin Gastroenterol 2005; 39:692-8.
  • 67. Myllyluoma E., Veijola L., Ahlroos T., et al. Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy – a placebo-controlled, double-blind randomized pilot study. Aliment Pharmacol Ther 2005; 21:1263-72.
  • 68. Tursi A., Brandimarte G., Giorgetti G.M., Modeo M.E. Effect of Lactobacillus casei supplementation on the effectiveness and tolerability of a new second-line 10-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection. Med Sci Monit 2004; 10: CR662-6.
  • 69. Isolauri E. Dietary modification of atopic disease: Use of probiotics in the prevention of atopic dermatitis. Curr Allergy Asthma Rep 2004; 4:270-5.
  • 70. Schmidt W.P. Model of the epidemic of childhood atopy. Med Sci Monit 2004; 10:HY5.
  • 71. Kalliomaki M., Isolauri E. Role of intestinal flora in the development of allergy. Curr Opin Allergy Clin Immunol 2003; 3:15-20.
  • 72. Rosenfeldt V., Benfeldt E., Valerius N.H., et al. Effect of probiotics on gastrointestinal symptoms and small intestinal permeability in children with atopic dermatitis. J Pediatr 2004; 145:612-6.
  • 73. Majamaa H., Isolauri E. Probiotics: a novel approach in the management of food allergy. J Allergy Clin Immunol 1997; 99:179-85.
  • 74. Research suggests potential role for probiotics in treating allergy. Infect Dis Childr 2003; 3:72.
  • 75. Kalliomaki M., Salminen S., Poussa T., et al. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet 2003; 361:1869-71.
  • 76. Rautava S., Kalliomaki M., Isolauri E. Probiotics during pregnancy and breast-feeding might confer immnomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol 2002; 109:119-21.
  • 77. Hanifin J.M., Cooper K.D., Ho V.C., et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association „Administrative Regulations for Evidence-Based Clinical Practice Guidelines“. J Am Acad Dermatol 2004; 50:391-404.
  • 78. Isolauri E., Arvola T., Sutas Y., et al. Probiotics in the management of atopic eczema. Clin Exp Allergy 2000; 30:1604-10.
  • 79. Kirjavainen P.V., Salminen S.J., Isolauri E. Probiotic bacteria in the management of atopic disease: underscoring the importance of viability. J Pediatr Gastroenterol Nutr 2003; 36:223-7.
  • 80. Rosenfeldt V., Benfeldt E., Nielsen S.D., et al. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J Allergy Clin Immunol 2003; 111:389-95.
  • 81. Weston S., Halbert A., Richmond P., Prescott S.L. Effects of probiotics on atopic dermatitis: a randomised controlled trial. Arch Dis Child 2005; 90:892-7.
  • 82. Viljanen M., Savilahti E., Haahtela T., et al. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy 2005; 60:494-500.
  • 83. Helin T., Haahtela S., Haahtela T. No effect of oral treatment with an intestinal bacterial strain, Lactobacillus rhamnosus (ATCC 53103), on birch-pollen allergy: a placebo-controlled double-blind study. Allergy 2002; 57:243-6.
  • 84. Wang M.F., Lin H.C., Wang Y.Y., Hsu C.H. Treatment of perennial allergic rhinitis with lactic acid bacteria. Treatment of perennial allergic rhinitis with lactic acid bacteria. Pediatr Allergy Immunol 2004; 15:152-8.
  • 85. Collet J.P., Burtin P., Gillet J., еt аl. Risk of infectious diseases in children attending different types of day-care setting. Respiration 1994; 61(Suppl 1):16-9.
  • 86. Nafstad P., Hagen J.A., Oie L., et al. Day care centers and respiratory health. Pediatrics 1999; 103:753-8.
  • 87. Hatakka K., Savilahti E., Ponka A., et al. Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. BMJ 2001; 322:1327.
  • 88. Weizman Z., Asli G., Alsheikh A. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics 2005; 115:5-9.
  • 89. Tubelius P., Stan V., Zachrisson A. Increasing work-place healthiness with the probiotic Lactobacillus reuteri: a randomised, double-blind placebo-controlled study. Environ Health 2005; 4:25.
  • 90. de Vrese M., Winkler P., Rautenberg P., et al. Effect of Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3, B. bifidum MF 20/5 on common cold episodes: a double blind, randomized, controlled trial. Clin Nutr 2005; 24:481-91.
  • 91. Dani C., Biadaioli R., Bertini G., et al. Probiotics feeding in prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm infants. A prospective double-blind study. Biol Neonate 2002; 82:103-8.
  • 92. Mastretta E., Longo P., Laccisaglia A., et al. Effect of Lactobacillus GG and breast-feeding in the prevention of rotavirus nosocomial infection. Pediatr Gastroenterol Nutr 2002; 35:527-31.
  • 93. Lawrence G., Tudehope D., Baumann K., et al. Enteral human IgG for prevention of necrotising enterocolitis: a placebo-controlled, randomised trial. Lancet 2001; 357:2090-4.
  • 94. Kafetzis D.A., Skevaki C., Costalos C. Neonatal necrotizing enterocolitis: an overview. Curr Opin Infect Dis 2003; 16:349-55.
  • 95. Hoyos A.B. Reduced incidence of necrotizing enterocolitis associated with enteral administration of Lactobacillus acidophilus and Bifidobacterium infantis to neonates in an intensive care unit. Int J Infect Dis 1999; 3:197-202.
  • 96. Millar M., Wilks M., Costeloe K. Probiotics for preterm infants? Arch Dis Child Fetal Neonatal Ed 2003; 88: F354-8.
  • 97. Lin H.C., Su B.H., Chen A.C., et al. Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2005; 115:1-4.
  • 98. Bin-Nun A., Bromiker R., Wilschanski M., et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. J Pediatr 2005; 147:192-6.
  • 99. Kaila M., Isolauri E., Soppi E., et al. Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain. Pediatr Res 1992; 32:141-4.
  • 100. Cadieux P., Burton J.G., Gardiner I., et al. Lactobacillus strains and vaginal ecology. JAMA 2002; 287:1940-1.
  • 101. Reid G., Bruce A. W., Taylor M. Instillation of Lactobacillus and stimulation of indigenous organisms to prevent recurrence of urinary tract infections. Microecol Ther 1995; 23:32-45.
  • 102. Reid G., Bruce A. W., Fraser N., et al. Oral probiotics can resolve urogenital infections. FEMS Immunol Med Microbiol 2001; 30:49-52.
  • 103. Eschenbach D.A., Thwin S.S., Patton D.L., et al. Influence of the normal menstrual cycle on vaginal tissue, discharge, and microflora. Clin Infect Dis 2000; 30:901-7.
  • 104. Galask R.P. Vaginal colonization by bacteria and yeast. Am J Obstet Gynecol 1988; 158:993-5.
  • 105. Eschenbach D.A., Patton D.L., Meier A., et al. Effects of oral contraceptive pill use on vaginal flora and vaginal epithelium. Contraception. 2000; 62:107-12.
  • 106. Schwebke J.R., Richey C.M., Weiss H.L. Correlation of behaviors with microbiological changes in vaginal flora. J Infect Dis 1999; 180:1632-6.
  • 107. Keane F.E., Ison C.A., Taylor-Robinson D. A longitudinal study of the vaginal flora over a menstrual cycle. Int J STD AIDS 1997; 8:489-94.
  • 108. Reid G., Burton J., Devillard E. The rational for probiotics in female urogenital healthcare. MedGenMed 2004; 6:49.
  • 109. Wilks M., Wiggins R., Whiley A., et al. Identification and H2O2 production of vaginal lactobacilli from pregnant women at high risk of preterm birth and relation with outcome. J Clin Microbiol 2004; 42:713-7.
  • 110. Vallor A.C., Antonio M.A., Hawes S.E., Hillier S.L. Factors associated with acquisition of, or persistent colonization by, vaginal lactobacilli: role of hydrogen peroxide production. J Infect Dis 2001; 184:1431-6.
  • 111. Sablon E., Contreras B., Vandamme E. Antimicrobial peptides of lactic acid bacteria: mode of action, genetics and biosynthesis. Adv Biochem Eng Biotechnol 2000; 68:21-60.
  • 112. Reid G., Charbonneau D., Erb J., et al. Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. FEMS Immunol Med Microbiol 2003; 35:131-4.
  • 113. Eriksson K., Carlsson B., Forsum U., Larsson P.G. A double-blind treatment study of bacterial vaginosis with normal vaginal lactobacilli after an open treatment with vaginal clindamycin ovules. Acta Derm Venereol 2005; 85:42-6.
  • 114. Pirotta M., Gunn J., Chondros P., et al. Effect of Lactobacillus in preventing post-antibiotic vulvovaginal candidiasis: a randomised controlled trial. BMJ 2004; 329:548.
  • 115. Klebanoff S.J., Hillier S.L., Eschenbach D.A., Waltersdorph A.M. Control of the microbial flora of the vagina by H2O2-generating lactobacilli. J Infect Dis 1991; 164:94-100.
  • 116. Sobel J.D., Chaim W. Vaginal microbiology of women with acute recurrent vulvovaginal candidiasis. J Clin Microbiol 1996; 34:2497-9.
  • 117. Colodner R., Edelstein H., Chazan B., Raz R. Vaginal colonization by orally administered Lactobacillus rhamnosus GG. Isr Med Assoc J 2003; 5:767-9.
  • 118. Rayes N., Seehofer D., Hansen S., et al. Early enteral supply of Lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation 2002; 74:123-7.
  • 119. Olah A., Belagyi T., Issekutz A., et al. Randomized clinical trial of specific Lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis. Br J Surg 2002; 89:1103-7.
  • 120. Bonn D. Probiotics reduce risk of gut infections. Lancet Infect Dis 2002; 2:716.
  • 121. Kajander K., Hatakka K., Poussa T., et al. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 2005; 22:387-94.
  • 122. Agerholm-Larsen L., Raben A., Haulrik N., et al. Effect of 8 week intake of probiotic milk products on risk factors for cardiovascular diseases. Eur J Clin Nutr 2000; 54:288-97.
  • 123. Naruszewicz M., Johansson M.L., Zapolska-Downar D., et al. Effect of Lactobacillus plantarum 299v on cardiovascular disease risk factors in smokers. Am J Clin Nutr 2002; 76:1249-55.
  • 124. Xiao J.Z., Kondo S., Takahashi N., et al. Effects of milk products fermented by Bifidobacterium longum on blood lipids in rats and healthy adult male volunteers. J Dairy Sci 2003; 86:2452-61.
  • 125. Heiser C.R., Ernst J.A., Barrett J.T., et al. Probiotics, soluble fiber, and L-Glutamine (GLN) reduce nelfinavir (NFV)- or lopinavir/ritonavir (LPV/r)-related diarrhea. J Int Assoc Physicians AIDS Care 2004; 3:121-9.
  • 126. Ahola A.J., Yli-Knuuttila H., Suomalainen T., et al. Short-term consumption of probiotic-containing cheese and its effect on dental caries risk factors. Arch Oral Biol 2002; 47:799-804.
  • 127. Nase L., Hatakka K., Savilahti E., et al. Effect of long-term consumption of a probiotic bacterium, Lactobacillus rhamnosus GG, in milk on dental caries and caries risk in children. Caries Res 2001; 35:412-20.
  • 128. Szajewska H., Kotowska M., Mrukowicz J.Z., et al. Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. J Pediatr 2001; 138:361-5.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared